Drug Profile
Research programme: miR-33 inhibitors - Roche
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital
- Developer Roche
- Class Antisense oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cardiovascular-disorders in Denmark (Parenteral)
- 28 Feb 2011 Early research in Cardiovascular disorders in Denmark (unspecified route)